Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
09926 AKESO, INC. - B
37.000
+5.850+18.78%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Turnover
26.85% 163.14M -- 225.63M -- 128.6M -- --
Operating income
26.85% 163.14M 225.63M 128.6M
Cost of sales
-- -28.11M -- -31.26M -- -- -- --
Operating expenses
-28.11M -31.26M
Gross profit
5.00% 135.03M 194.37M 128.6M
Selling expenses
-- -149.5M -- -179.15M -- -- -- --
Administrative expenses
-27.88% -92.74M 3.76% -243.52M 27.13% -72.52M -356.56% -253.03M
Research and development expenses
-5.65% -595.38M -46.11% -1.12B -134.11% -563.52M -149.23% -768.59M
Revaluation surplus
-- -- -- -- -- -- -323.51% -412.42M
-Changes in the fair value of other assets
-- -- -- -- -- -- -323.51% -412.42M
Special items of operating profit
-59.09% 26.55M -14.79% 103.48M 59.12% 64.89M 144.88% 121.45M
Operating profit
-52.76% -676.05M 4.94% -1.25B 37.83% -442.55M -285.24% -1.31B
Financing cost
-338.02% -15.83M -29.61% -10.35M 44.15% -3.61M -39.24% -7.99M
Earning before tax
-55.07% -691.88M 4.73% -1.26B 37.89% -446.16M -281.17% -1.32B
After-tax profit from continuing operations
-55.07% -691.88M 4.73% -1.26B 37.89% -446.16M -281.17% -1.32B
Earning after tax
-55.07% -691.88M 4.73% -1.26B 37.89% -446.16M -281.17% -1.32B
Minority profit
-189.05% -61.45M -27.64% -183.19M 53.32% -21.26M -1,196.78% -143.53M
Profit attributable to shareholders
-48.37% -630.43M 8.68% -1.07B 36.84% -424.9M -250.95% -1.18B
Basic earnings per share
-48.08% -0.77 20.00% -1.32 53.98% -0.52 39.78% -1.65
Diluted earnings per share
-48.08% -0.77 20.00% -1.32 53.98% -0.52 39.78% -1.65
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--Ernst & Young accounting firm--Ernst & Young accounting firm

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs affordable to patients around the world. Since its inception, the company has established an end-to-end omni-directional drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development and GMP-compliant production. The company has also successfully developed bispecific antibody drug development technology (TETRABODY technology), which helps us overcome three CMC difficulties encountered in the development and production of bispecific antibodies, including inefficient expression levels, process development obstacles, and antibody stability and properties. The company currently has more than 30 innovative drug product lines for the treatment of cancer, autoimmune, inflammation, metabolic diseases and other major diseases, of which 15 varieties have entered the clinical stage, including two international first bispecific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The company hopes to become a leading biopharmaceutical company in the world through efficient and innovative research and development of new drugs of the same kind or the best treatment of the same kind.
CEO: Yu Xia
Market: Hong Kong motherboard
Listing Date: 04/24/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist